Amedeo Smart

Free Medical Literature Service


 

Amedeo

Gynecology

  Free Subscription

Articles published in
Anticancer Res
    November 2026
  1. UTSUMI N, Kawamura H, Yamano T, Hayakawa T, et al
    Retrospective Study of Pelvic Irradiation in Patients With Advanced Uterine Cervical Cancer.
    Anticancer Res. 2026;46:6175-6182.
    >> Share

  2. MICHALSKI K, Kosmala A, Kohnle P, Heinrich M, et al
    (68)Ga-FAPI-04 PET/CT for Detection of Locoregional Lymph Node Metastases in Gynecologic Squamous Cell Carcinoma.
    Anticancer Res. 2026;46:6319-6329.
    >> Share

    September 2026
  3. XU P, Xiang M, Liu F
    Advances in Gynecologic Tumor-associated Lymphatic Vessels.
    Anticancer Res. 2026;46:4797-4812.
    >> Share

    August 2026
  4. SCHRODER C, Qureischi M, Hecking T, Nadal J, et al
    Tumoral PD-L1 Expression as a Prognostic Marker in Invasive Cervical Cancer.
    Anticancer Res. 2026;46:4371-4383.
    >> Share

    July 2026
  5. HU Y, Song Z, Li J, Yang F, et al
    Targeting the LRIG2-PI3K/AKT/mTOR Axis to Induce Apoptosis: A Novel Antitumor Mechanism of Verbascoside in Endometrial Cancer Cells.
    Anticancer Res. 2026;46:3733-3753.
    >> Share

  6. KANG OJ, Kim Y, Nam SH, Lee SW, et al
    Gastric-type Histology Independently Predicts Poor Survival in Surgically-treated Cervical Adenocarcinoma.
    Anticancer Res. 2026;46:3927-3937.
    >> Share

  7. NAKAI M, Yoshida K, Morita H, Kawamura Y, et al
    Association Between Brachytherapy and Acute Diarrhea During Chemoradiotherapy for Cervical Cancer: A Multicenter Retrospective Study.
    Anticancer Res. 2026;46:3907-3917.
    >> Share

    June 2026
  8. TORMANEN H, Huhtamaki H, Holster T, Puistola U, et al
    Prior Chlamydia trachomatis Infection and the Risk of Epithelial Ovarian Cancer and Borderline Ovarian Tumors.
    Anticancer Res. 2026;46:3257-3265.
    >> Share

  9. SEKSAF NA, Roberts HL, Lewis ME, Smits A, et al
    Quality of Life Outcomes Following Pelvic Exenteration for Gynaecological Malignancies: A Systematic Review.
    Anticancer Res. 2026;46:2945-2963.
    >> Share

  10. MORGENSTERN B, Schmidt M, Thangarajah F
    Dual Modality and Site-differentiated Sentinel Node Mapping in Vulvar Cancer.
    Anticancer Res. 2026;46:3417-3423.
    >> Share

    May 2026
  11. SALIMIAGHDAM N, Yang X, Liang H
    The Ovarian Portal: An Unusual Pathway to Discovery, A Rare Initial Manifestation of Colon Cancer.
    Anticancer Res. 2026;46:2915-2923.
    >> Share

  12. BIEGANSKA O, Biczak E, Przywara G, Blok R, et al
    Ovarian Sertoli Cell Tumor Coexisting With Uterine Malformation: A Case Report.
    Anticancer Res. 2026;46:2925-2936.
    >> Share

  13. CHANG WS, Tsai CW, Chen JC, Wang YC, et al
    Inflammatory Cytokine Genotypic Markers and Ovarian Cancer Risk.
    Anticancer Res. 2026;46:2863-2876.
    >> Share

  14. HOGDALL EV, Vestergaard LK, Oliveira DNP, Poulsen TS, et al
    Ascites: A Potential Diagnostic Surrogate for Genetic Profiling in Ovarian Cancer.
    Anticancer Res. 2026;46:2899-2913.
    >> Share

  15. OZAWA Y, Tanigawa H, Fujimiya T, Abe Y, et al
    Risk Factors for Niraparib-induced Severe Anemia in Japanese Patients With Ovarian Cancer: A Multicenter Study.
    Anticancer Res. 2026;46:2887-2897.
    >> Share

  16. TANISKIDI A, Giannas E, Lekka S, Taniskidi A, et al
    Recurrence and Malignant Transformation After Borderline Ovarian Tumors: A Systematic Review and Meta-analysis.
    Anticancer Res. 2026;46:2831-2849.
    >> Share

  17. MIYATA K, Yotsumoto F
    Metabolism-driven Immune Escape Defines Therapeutic Vulnerability in Type I and Type II Ovarian Cancer.
    Anticancer Res. 2026;46:2851-2861.
    >> Share

  18. AVSAR H, Eroglu I, Demirci A, Gonul II, et al
    Ovarian Metastasis from EBV-Associated Undifferentiated Nasopharyngeal Carcinoma: An Exceptionally Rare Occurrence.
    Anticancer Res. 2026;46:2937-2943.
    >> Share

  19. DAWOOD M, Ooko E, Efferth T, Boulos JC, et al
    Prognostic Relevance of FOS and JUN Family Members and Immune Cell Infiltration for the Survival of Patients With Ovarian Carcinoma.
    Anticancer Res. 2026;46:2877-2886.
    >> Share

  20. PLATSOUCAS CD
    Ovarian Carcer Immunology and Immunotherapy: Editorial Note.
    Anticancer Res. 2026;46:2829.
    >> Share

    April 2026
  21. SARKAR S, Saha A, DAS B, DAS D, et al
    Phosphodiesterase 5 Inhibitor Sildenafil Inhibits HPV(+) Cervical Cancer Cells and Cervical Cancer Stem Cells by Apoptotic Induction and Telomerase Activity Modulation.
    Anticancer Res. 2026;46:2007-2024.
    >> Share

  22. MICHA JP, Bohart R, Goldstein BH
    The Impact of Exercise and Diet on Ovarian Cancer Mortality.
    Anticancer Res. 2026;46:1763-1768.
    >> Share

  23. PARKER JM, Williams LR, Haines NA, Mayberry TG, et al
    Unveiling the Molecular Blueprint of Spinach Induced Anti-proliferation and Pro-apoptosis in Cervical Cancer.
    Anticancer Res. 2026;46:1833-1841.
    >> Share

  24. HELMS L, Sabiani L, Djemouai S, Rambeaud C, et al
    Impact of Biopsy Diagnostic Methods on the Prognosis of Stage I Endometrioid Cancer.
    Anticancer Res. 2026;46:2105-2114.
    >> Share

    March 2026
  25. TONOMURA N, Yoshida K, Morita H, Nakai M, et al
    Diuretic Administration for Vomiting During Concurrent Chemoradiotherapy for Cervical Cancer: A Multicenter Retrospective Study.
    Anticancer Res. 2026;46:1497-1506.
    >> Share

  26. MASUMOTO S, Tanaka M, Yamamoto K, Hori Y, et al
    HPV18-positive Small Cell Neuroendocrine Carcinoma of the Uterine Cervix Treated With Immunotherapy: A Case Report.
    Anticancer Res. 2026;46:1733-1739.
    >> Share

  27. ONISHI T, Niimi H, Kumazaki A, Masaki Y, et al
    EZH2 Expression Is Associated With Sensitivity to Inhibitors and Promotes Malignancy in Endometrial Cancer Cells.
    Anticancer Res. 2026;46:1259-1269.
    >> Share

  28. MICHA JP, Bohart RD, Gorman JP, Goldstein BH, et al
    Primary Debulking Surgery Versus Interval Debulking Surgery in the Management of Advanced-Stage Ovarian Cancer.
    Anticancer Res. 2026;46:1175-1182.
    >> Share

  29. DIEDRICH D, Silva EF, Willig JB, Ruaro TC, et al
    The Privileged Scaffold Quinoline in Derivatives With Anticancer Potential Mediated by Late Apoptosis.
    Anticancer Res. 2026;46:1475-1487.
    >> Share

  30. TSUJI M, Kobayashi K, Kawakami K, Fukuda N, et al
    Real-world Analysis of Urinary Protein-to-Creatinine Ratio and Blood Pressure in Lenvatinib Therapy.
    Anticancer Res. 2026;46:1651-1659.
    >> Share

    February 2026
  31. FUCINA S, Lerda L, Bartoletti M, Perin A, et al
    Postmenopausal Stage IV Ovarian Yolk Sac Tumor With Neuroendocrine Features: Report of a Rare Case.
    Anticancer Res. 2026;46:1167-1172.
    >> Share

  32. NISCO A, Tolomeo M, Sposato A, Paleni D, et al
    Alteration of Flavin Homeostasis in Uterine Cancer.
    Anticancer Res. 2026;46:681-688.
    >> Share

  33. SAGER G, Livik M, Hellevik T, Orbo A, et al
    Extracellular cGMP Levels Predict the Response of C4-1 Cervical Cancer Cells to Ionizing Radiation.
    Anticancer Res. 2026;46:611-618.
    >> Share

  34. CHECK JH, Check DL, Ganpo-Nkewnkwa N
    Marked Palliative Benefits Seen With Treatment of Very Advanced Breast Cancer With the Progesterone Receptor Modulator Mifepristone.
    Anticancer Res. 2026;46:1153-1165.
    >> Share

    January 2026
  35. HOSHINO N, Yoshida K, Kanemitsu Y, Toyama A, et al
    Individualized Estimated Glomerular Filtration Rate-based Renal Function Association With Cisplatin Treatment Completion in Cervical Cancer.
    Anticancer Res. 2026;46:273-281.
    >> Share

  36. EGGER E, Forster S, Adloff L, Marinova M, et al
    Paucimannosylation Is a Prognostic Marker in High-grade Serous Ovarian Cancer.
    Anticancer Res. 2026;46:85-94.
    >> Share

    December 2025
  37. NAKAO T, Harano K, Wakabayashi M, Taki T, et al
    Prognostic Value of Tertiary Lymphoid Structures in Epithelial Ovarian Carcinoma.
    Anticancer Res. 2025;45:5543-5555.
    >> Share

  38. NAYAB M, Elnaggar M, Asher V, Bali A, et al
    Comparative Analysis of FDG-PET Versus CT/MRI in Staging and Management of Advanced-stage Cervical Cancer.
    Anticancer Res. 2025;45:5503-5511.
    >> Share

  39. TAKATORI E, Shoji T, Jo A, Musashi M, et al
    Efficacy of Platinum-based Chemotherapy for Platinum-sensitive Recurrent Ovarian Cancer During PARP Inhibitor Treatment: A Multicenter Retrospective Study.
    Anticancer Res. 2025;45:5773-5783.
    >> Share

  40. SCHULTZ A, Peters F, Jobst N, Gebauer G, et al
    Impact of the Introduction of the S3 Guideline on the Management of Primary Endometrial Cancer: A Comparative Analysis of Cancer Registry Data from Hamburg (2014-2022).
    Anticancer Res. 2025;45:5533-5542.
    >> Share

  41. CHATTERJEE R, Cocking A, Eddama M, Kolomainen D, et al
    Surgical and Oncologic Outcomes in Uterine Carcinosarcoma: A Retrospective Cohort Analysis.
    Anticancer Res. 2025;45:5523-5531.
    >> Share

  42. DAO THL, Nakamura K, Okamoto K, Vu TH, et al
    Leucine-rich Repeat-containing 15 as a Potential Marker and Therapeutic Target in Cervical Cancer.
    Anticancer Res. 2025;45:5409-5421.
    >> Share

  43. ASANO Y, Sato T, Hozumi C, Han Q, et al
    FDG- and MET-PET Imaging Reveal Glucose and Methionine Addiction in a Primary Endometrial Cancer and Methionine Addiction only in a Para-aortic Lymph-node Metastasis in a 58-year-old Patient.
    Anticancer Res. 2025;45:5819-5824.
    >> Share

  44. CHECK JH, Check DL, Wilson C
    Good Quality 66.7% 5-year Overall Survival in Terminal Lung Cancer Patients Treated With Mifepristone.
    Anticancer Res. 2025;45:5785-5798.
    >> Share

    November 2025
  45. ITO Y, Nakamura K, Nakagawa-Saito Y, Suzuki S, et al
    The MDM4 Inhibitor CEP-1347 Activates Wild-type p53 in Ovarian Clear Cell Carcinoma Cells and Potently Inhibits their Growth.
    Anticancer Res. 2025;45:4881-4890.
    >> Share

  46. YOO SS, Banish K, Fahmi A, Glasener C, et al
    Focused Ultrasound-mediated Disruption of Plasma Protein Binding Enhances Chemotherapeutic Effects of Paclitaxel on Xenografted Ovarian Cancer in Mice.
    Anticancer Res. 2025;45:4697-4715.
    >> Share

  47. ITO Y, Nakamura K, Nakagawa-Saito Y, Takenouchi S, et al
    Senolytic Elimination of Senescent Ovarian Clear Cell Carcinoma Cells Induced by CEP-1347 With the BH3 Mimetic Navitoclax.
    Anticancer Res. 2025;45:4841-4851.
    >> Share

  48. DELL'ATTI L
    Management of Bladder Cancer During Pregnancy: A Narrative Review.
    Anticancer Res. 2025;45:4689-4695.
    >> Share

    October 2025
  49. BARAT S, Ahmadi N, Wijayawardana R, Liauw W, et al
    Survival Outcomes Post-secondary Cytoreduction in Peritoneal Metastatic Cases from Ovarian Cancer: A Single Institute Study.
    Anticancer Res. 2025;45:4281-4293.
    >> Share

  50. HIKINO K, Komatsu H, Kazuki Y, Kazuki K, et al
    Matrix Metalloproteinase-1 as an Independent Prognostic Biomarker in Epithelial Ovarian Carcinoma.
    Anticancer Res. 2025;45:4473-4481.
    >> Share

    September 2025
  51. PARK SJ, Koh JW, Lee TB, Han SI, et al
    Biological Role of Replication Factor C Subunit 4 in Cervical Cancer Cell Progression.
    Anticancer Res. 2025;45:3701-3710.
    >> Share

  52. FURUKAWA S, Soeda S, Endo H, Yoshimoto Y, et al
    Multidisciplinary Therapy of Uterine Ewing's Sarcoma With the Preservation of Uterus and Ovarian Function by Laparoscopy: A Case Report and Literature Review.
    Anticancer Res. 2025;45:4027-4035.
    >> Share

    August 2025
  53. MUKOHYAMA J, Saito I, Mochizuki S, Ota Y, et al
    Endometrial Cancer Metastatic to the Sigmoid Colon and Pelvic Retroperitoneal Space: A Case Report.
    Anticancer Res. 2025;45:3567-3573.
    >> Share

  54. AKAZAWA M, Hashimoto K, Nagano H
    Development and External Validation of Machine Learning-based Models for Predicting Survival Outcomes in Endometrial Cancer: A Population-based Study.
    Anticancer Res. 2025;45:3543-3551.
    >> Share

  55. KIYOSHIMA C, Urushiyama D, Yoshikawa K, Ishida K, et al
    microRNA in Chorioamnionitis: Emerging Biomarkers for Early Diagnosis.
    Anticancer Res. 2025;45:3587-3594.
    >> Share

    July 2025
  56. LI M, Yan J, Wei S, Zhao S, et al
    Macranthoside B Enhances Paclitaxel-induced Human Cervical Cancer Cell Apoptosis Through ROS-JNK Pathway.
    Anticancer Res. 2025;45:2859-2870.
    >> Share

  57. MICHA JP, Bohart RD, Gorman JP, Goldstein BH, et al
    Immunotherapy and Chemotherapy for Advanced or Recurrent Endometrial Carcinoma.
    Anticancer Res. 2025;45:2711-2717.
    >> Share

  58. CRISPO A, Luongo A, Nocerino D, Cascella M, et al
    Assessment of Breakthrough Cancer Pain Among Female Patients With Cancer: Knowledge, Management and Characterization in the IOPS-MS Study.
    Anticancer Res. 2025;45:3149-3164.
    >> Share

    May 2025
  59. WEHBE S, Gallwas J, Grundker C
    Inhibition of Plasminogen Activator Inhibitor-1 (PAI-1) by Tiplaxtinin Reduces Aggressiveness of Cervical Carcinoma Cells.
    Anticancer Res. 2025;45:1793-1805.
    >> Share

  60. BAL J, Fulawka L, Gabrys M, Murawski M, et al
    Potential Role of PTEN and AKT/PKB Proteins in the Pathogenesis of Ovarian Mature Teratomas.
    Anticancer Res. 2025;45:1843-1851.
    >> Share

  61. SIMONETTI E, Pistolesi S, Ferrari A, Della Rosa M, et al
    Role of Stromal CD25+/CD8+ Lymphocyte Ratio in Patients With Grade 2-3 Cervical Intraepithelial Neoplasia (CIN 2-3): A Retrospective Single-center Study.
    Anticancer Res. 2025;45:2041-2050.
    >> Share

  62. TSUKAMOTO YO, Ohtsuka T, Yamauchi Y, Mun M, et al
    Efficacy and Prognostic Factors of Surgical Resection for Pulmonary Metastases From Ovarian Cancer.
    Anticancer Res. 2025;45:2071-2078.
    >> Share

    April 2025
  63. DAMPALI R, Nikolettos K, Psilopatis I, Kostaki EG, et al
    The Impact of Body Mass Index on Sentinel Lymph Node Identification in Endometrial Cancer.
    Anticancer Res. 2025;45:1575-1581.
    >> Share

    March 2025
  64. WU YC, Ku MH, Huang WL, Dias L, et al
    NEAT1 in Ovarian Cancer: A Key Regulator of Tumor Progression, Follicular Fluid Dynamics, and Therapeutic Resistance.
    Anticancer Res. 2025;45:825-842.
    >> Share

  65. AHMADU T, Olawade DB, Teke J, Bachour ME, et al
    Diagnosis and Treatment of Gestational Non-Epithelial Ovarian Cancer: A Systematic Review.
    Anticancer Res. 2025;45:843-853.
    >> Share

  66. KOH JW, Park SJ
    Knockdown of RFC2 Prevents the Proliferation, Migration and Invasion of Cervical Cancer Cells.
    Anticancer Res. 2025;45:989-1000.
    >> Share

    February 2025
  67. STUEBS FA, Dietl AK, Schulmeyer CE, Behrens AS, et al
    Prognostic Significance of the Detection of Human Papilloma Virus L1 Protein in Smears of Cervical Intraepithelial Neoplasia Grade 3 in Pregnant Women.
    Anticancer Res. 2025;45:677-683.
    >> Share

  68. SANTANA BN, Arencibia O, Babin G, Tommasetti E, et al
    Use of Indocyanine Green Fluorescence Angiography to Assess Bowel Anastomosis in Ovarian Cancer Surgery.
    Anticancer Res. 2025;45:661-666.
    >> Share

  69. SHIEH PC, Shih HY, Chuang CL, Tsai CW, et al
    Association of Matrix Metalloproteinase-1 Promoter Genotypes With Endometriosis Risk.
    Anticancer Res. 2025;45:465-471.
    >> Share

    January 2025
  70. TALIJANOVIC M, Lopacinska-Jorgensen J, Hogdall EV
    Gene Expression Profiles in Ovarian Cancer Tissues as a Potential Tool to Predict Platinum-based Chemotherapy Resistance.
    Anticancer Res. 2025;45:11-26.
    >> Share

  71. KARSTENSEN S, Kaiser K, Poulsen TS, Jochumsen K, et al
    Ovarian Adult Granulosa Cell Tumors: A Scoping Review of DNA Alterations and Their Known Significance.
    Anticancer Res. 2025;45:1-10.
    >> Share

  72. LINDQVIST PG, Gissler M
    Improved Vitamin D Status Is Associated With Lower Incidence of Stillbirth.
    Anticancer Res. 2025;45:243-250.
    >> Share

    December 2024
  73. KONTOMANOLIS E, Koutras A, Mitrakas AG, Trypsianis G, et al
    Tissue Expression and Plasma Soluble PD-L1 Levels in Patients With Endometrial Cancer.
    Anticancer Res. 2024;44:5525-5530.
    >> Share

  74. ULKER EB, Aktas EC, Seyhan MF, Isbir T, et al
    Effects of Curcumin and Its Analogue Desmethoxycurcumin on miR-133b and Its Target Gene GSTP-1 in Cisplatin-resistant Ovarian Cancer Cells.
    Anticancer Res. 2024;44:5351-5359.
    >> Share

  75. CHO Y, Kim HS
    Immunohistochemical Expression and Significance of Preferentially Expressed Antigen in Melanoma (PRAME) in Gynecological Tumors: A Single-institution Retrospective Analysis.
    Anticancer Res. 2024;44:5515-5524.
    >> Share

    November 2024
  76. LENZ C, Gesemann L, Al-Baldawi Y, Pusken M, et al
    Accuracy of Preoperative Magnet Resonance Imaging to Predict Pathologic T-Stage in Patients With Cervical Cancer.
    Anticancer Res. 2024;44:5081-5085.
    >> Share

  77. NA JM, Kim HS
    Comprehensive Clinicopathological and Immunohistochemical Analysis of Human Papillomavirus-independent Squamous Cell Carcinoma and Adenosquamous Carcinoma of the Uterine Cervix.
    Anticancer Res. 2024;44:4969-4981.
    >> Share

  78. COCCHI S, Lopacinska-Jorgensen J, Hogdall EV
    Potential Transcriptomic Biomarkers for Predicting Platinum-based Chemotherapy Resistance in Patients With High-grade Serous Ovarian Cancer.
    Anticancer Res. 2024;44:4691-4707.
    >> Share

  79. LEE HM, Cho HJ, Lee YM, Kim HJ, et al
    Fostamatinib Inhibits the Proliferation of Ovarian Cancer Cells Through Apoptosis Induction.
    Anticancer Res. 2024;44:4895-4903.
    >> Share

  80. SIN J, Kiosea M, Mahdavi K, Akbarpour F, et al
    Investigation of the Efficacy of Nowarta110 in the Treatment of HPV-16 and HPV-18 Oncogenically-transformed Human Cells and Cancer-implanted Animal Models.
    Anticancer Res. 2024;44:4723-4728.
    >> Share

  81. LEE J, Chi SA, Choi S, Kim HS, et al
    Invasive Stratified Mucin-producing Carcinoma of the Uterine Cervix: Comparison of Its Clinicopathological Characteristics and Programmed Death-ligand 1 Expression Status With Those of Other Endocervical Adenocarcinomas.
    Anticancer Res. 2024;44:5007-5022.
    >> Share

    October 2024
  82. SANTANA BN, Guyon F, Arencibia O, Babin G, et al
    Factors Limiting Ostomy Reversal After Cytoreductive Surgery for Ovarian Cancer: A Retrospective Study.
    Anticancer Res. 2024;44:4413-4418.
    >> Share

  83. LEE J, Heo K
    Repurposing Valrubicin as a Potent Inhibitor of Ovarian Cancer Cell Growth.
    Anticancer Res. 2024;44:4301-4307.
    >> Share

  84. HA H, Ryu JY, Yoon S, Cho YJ, et al
    Anticancer Effects of BAF312 (Siponimod) in Epithelial Ovarian Cancer.
    Anticancer Res. 2024;44:4273-4282.
    >> Share

    September 2024
  85. SMOLARZ B, Lukasiewicz H, Samulak D, Kolacinski R, et al
    Hypoxia-induced Factor-1alpha and its Role in Endometrial Cancer.
    Anticancer Res. 2024;44:3697-3712.
    >> Share

    August 2024
  86. KYRIAZOGLOU A, Papachristou DJ, Moutafi M, Papakosta A, et al
    Implications of the Hippo Pathway Dysregulation in Uterine Leiomyosarcoma.
    Anticancer Res. 2024;44:3331-3336.
    >> Share

  87. HIRAKAWA T, Yotsumoto F, Imi S, Ito N, et al
    Adipose-derived Mesenchymal Stem Cell Transplantation Improves Ovarian Function and Oocyte Quality in Aged Mice.
    Anticancer Res. 2024;44:3577-3586.
    >> Share

    July 2024
  88. LI Q, Guan T, Mao J, King BP, et al
    Mast Cell-related Prognosis Signature Characterizes Immune Landscape and Predicts Prognosis of Ovarian Cancer.
    Anticancer Res. 2024;44:2775-2786.
    >> Share

  89. CHIEN HJ, Wang YC, Chang WS, Hsieh YH, et al
    Contribution of Matrix Metalloproteinase-7 Genotypes to Endometriosis Risk in Taiwan.
    Anticancer Res. 2024;44:3051-3058.
    >> Share

  90. CHOI EY, Han EJ, Jeon SJ, Lee SW, et al
    Kaempferol Inhibits Cervical Cancer Cells by Inducing Apoptosis and Autophagy via Inactivation of the PI3K/AKT/mTOR Signaling Pathway.
    Anticancer Res. 2024;44:2961-2972.
    >> Share

  91. MAFUNE S, Someya M, Hasegawa T, Tsuchiya T, et al
    Analysis of Treatment Response With Proteins Related to Tumor Immunity in Postoperative Irradiated Cervical Cancer Patients.
    Anticancer Res. 2024;44:3077-3086.
    >> Share

  92. ZHANG Y, Niu X, Wang Y, Bao S, et al
    SIRT4 Has an Anti-Cancer Role in Cervical Cancer by Inhibiting Glutamine Metabolism via the MEK/ERK/C-Myc Axis.
    Anticancer Res. 2024;44:2861-2870.
    >> Share

    June 2024
  93. LEONHARDI J, Horn LC, Aktas B, Denecke T, et al
    MRI Texture Analysis of Inguinal Lymph Node Metastasis in Vulvar Cancer - Associations With Histopathology.
    Anticancer Res. 2024;44:2709-2716.
    >> Share

  94. MORGENSTERN B, Thangarajah F, Schmidt M, Lenz C, et al
    Clinical Impact of Pelvic Sentinel Lymph Node Biopsy for Vulvar Squamous Cell Carcinoma.
    Anticancer Res. 2024;44:2621-2626.
    >> Share

  95. KITSOS-KALYVIANAKIS K, Pitsikakis K, Mamalis ME, Kalampokis E, et al
    Continuity Unveiled: Evaluating Cytoreduction Outcomes for Advanced Ovarian Cancer Amidst the COVID-19 Era at an ESGO Designated Centre of Excellence.
    Anticancer Res. 2024;44:2645-2652.
    >> Share

    May 2024
  96. YAMAOKA Y, Tamura S, Yamanoi K, Taki M, et al
    Clinical Significance of Serum SCC Levels Before Treatment for Locally Advanced Cervical Squamous Cell Carcinoma.
    Anticancer Res. 2024;44:2009-2019.
    >> Share

  97. JUNG BC, Woo SH, Kim SH, Kim YS, et al
    Parkin Enhances Gefitinib-induced Anoikis in HeLa Cervical Cancer Cells.
    Anticancer Res. 2024;44:1853-1862.
    >> Share

  98. WILLSON CM, Lequio M, Zhu Z, Wakefield MR, et al
    The Role of SARS-CoV-2 Spike Protein in the Growth of Cervical Cancer Cells.
    Anticancer Res. 2024;44:1807-1815.
    >> Share

  99. KUM SJ, Jung YY, Kim HS
    Comparison of Clinicopathological and Prognostic Characteristics Between Minimal Deviation Adenocarcinoma and Gastric-type Endocervical Adenocarcinoma.
    Anticancer Res. 2024;44:2193-2204.
    >> Share

  100. MOREA A, Saravi S, Sisu C, Hall M, et al
    Effect of MYC and PARP Inhibitors in Ovarian Cancer Using an In Vitro Model.
    Anticancer Res. 2024;44:1817-1827.
    >> Share

    April 2024
  101. XU X, Wang Q, Shen L, Shen Y, et al
    Anlotinib Inhibits Ovarian Cancer and Enhances Cisplatinum Sensitivity via Suppressing NOTCH2 Expression and Stemness.
    Anticancer Res. 2024;44:1399-1407.
    >> Share

  102. TSENG CC, Ku MH, Wu YC, Huang WL, et al
    Therapeutic Options Targeting the Ataxia-Telangiectasia Mutated (ATM)-mediated DNA Damage Response, Macropinocytosis, and Adaptive Immunity in Ovarian Cancer.
    Anticancer Res. 2024;44:1353-1364.
    >> Share

  103. CHU J, Lee SH, DO SI, Kim HS, et al
    Clinicopathological Significance of Nucleosome Remodeling and Deacetylase Complex Expression in Endometrial Carcinoma.
    Anticancer Res. 2024;44:1739-1750.
    >> Share

  104. AOSHIKA T, Noda SE, Abe T, Kumazaki YU, et al
    Results of Definitive (Chemo)radiotherapy Using Computed Tomography-based Brachytherapy for Cervical Cancer.
    Anticancer Res. 2024;44:1583-1589.
    >> Share

  105. WANG X, Li C, Lou L, Zhu H, et al
    Roles of Matrix Metalloproteinases 2 and 9 in Uterine Leiomyosarcoma.
    Anticancer Res. 2024;44:1465-1473.
    >> Share

    March 2024
  106. KIM JS, Shin MJ, Lee SY, Choi SM, et al
    BBT-877, a Novel Autotaxin Inhibitor, Abrogates Drug Resistance in Epithelial Ovarian Cancer Stem Cells.
    Anticancer Res. 2024;44:1131-1142.
    >> Share

    October 2023
  107. SAILLANT A, Rasclard M, Gaume JB, Souchaud O, et al
    A Case of Anti-3-hydroxy-3-methylglutaryl-coenzyme A Reductase Myopathy Associated With Advanced Cervical Carcinoma.
    Anticancer Res. 2023;43:4723-4727.
    >> Share

  108. LIAKOU C, Pandraklakis A, LA Russa MC, Turnbull H, et al
    Interval Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy for Ovarian Cancer: Report of a Single-center Experience.
    Anticancer Res. 2023;43:4593-4599.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016